Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any gender
- People who have not previously received any treatment for their DLBCL (diffuse large B-cell lymphoma), including chemotherapy, targeted therapy, or immunotherapy
- People who have been confirmed by pathology (laboratory tissue testing) to have a specific type of DLBCL where two particular proteins — MYC and BCL2 — are both highly active (called "double expression"), OR people whose DLBCL does not meet that definition but who have at least one of the following: certain gene mutations including TP53 or other specific genetic changes as listed in the trial criteria, or a specific genetic finding called "MYC and BCL2 double hit" (confirm with trial site for details on which gene mutations apply)
- People who are planned to receive, or are already receiving, a treatment plan that includes a medicine called tucidinostat (including cases where tucidinostat may be added after genetic test results become available)
- People who are willing to sign an informed consent form agreeing to take part
Who may not be able to join:
- People who are currently enrolled in, or planning to join, any other interventional clinical trial
- People whose expected survival is less than 6 months
- People where the trial investigators have identified any other reason they consider participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13564015001
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
EFS（Event-free survival）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.